Want to see ZYME full AI Analyst Report?
ZYME Stock Chart & Stats
$27.47
$0.14(0.61%)
At close: 4:00 PM EDT
$27.47
$0.14(0.61%)
Day’s Range― - ―
52-Week Range$14.06 - $31.34
Previous Close$23
Volume259.30K
Average Volume (3M)597.02K
Market Cap
$2.22B
Enterprise Value$1.91K
Total Cash (Recent Filing)$270.70M
Total Debt (Recent Filing)$268.64M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 10, 2026EPS Estimate
2.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding70,959,240
10 Day Avg. Volume866,375
30 Day Avg. Volume597,016
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.20Price Target Upside46.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.46
Revenue Forecast (FY)$312.10M
Bulls Say, Bears Say
Bulls Say
Strong Cash Position And RunwayThe substantially higher cash balance provides funding flexibility for clinical development and operations. Management expects cash plus anticipated milestones to support operations beyond 2028, although this depends on successful execution.
Promising Clinical And Platform PipelineEncouraging ZW191 activity supports the potential for a differentiated oncology asset, while the pan-RAS ADC platform broadens future opportunities. Multiple programs diversify long-term value creation beyond a single partnered medicine.
Potential Revenue Diversification From TheravanceAdding marketed-product profit sharing and royalties could reduce reliance on episodic development milestones and create a more durable revenue base. The transaction may also provide cash flow to support Zymeworks’ pipeline and strategic investments.
Bears Say
Volatile Revenue, Losses And Cash BurnThe company lacks a stable earnings base, with revenue dependent on irregular milestones and development support. Persistent losses and negative operating and free cash flow require continued funding, increasing sensitivity to pipeline timing and financing assumptions.
Dependence On Partners And External PricingPartner-controlled launches, approvals and commercial terms determine a substantial portion of potential revenue. Delays, weaker sales or pricing restrictions could reduce milestone and royalty inflows, limiting the predictability of long-term cash generation.
Pipeline Timing And Execution RiskProgram delays defer potential clinical validation and increase the time before new assets can contribute strategic or financial value. Preclinical manufacturing, CMC and partnering decisions add execution dependencies across the broader pipeline.
Zymeworks News
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $14.05 and its highest was $31.34 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $2.22B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Nov 10, 2026 which is in 66 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Aug 06, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.575 by -$0.045.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is 2.42.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 70,959,240 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.575. Following the earnings report the stock price went up 1.773%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.20 (46.34% Upside)
$40.20 (46.34% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 343.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zymeworks Inc
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$40.20
▲(46.34% Upside)
Technical Analysis
Xencor
―
AnaptysBio
―
Vir Biotechnology
―
AbCellera Biologics
―
Generate Biomedicines, Inc.
―
Ownership Overview
1.31% Insiders
8.71% Mutual Funds
64.63% Other Institutional Investors
14.81% Public Companies and
Individual Investors